Neurocrine Biosciences Stock News

State of Alaska Department of Revenue trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,526 shares of the companys stock after selling 157 shares during the quarter. State of []

San Diego-based company plans to develop medications for neurological disorders Related Stocks: NBIX , SOLTF , LLY , PFE , MRK , BMY , AZN , GSK , AMGN , SNY , FRA:SNY , STU:SNY ,

Following disappointing third-quarter earnings, Neurocrine Biosciences, Inc. ( NBIX , Financial) shareholders were looking for a shred of good news that could boost the price of the San-Diego-based bi

Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a new drug candidate from Sosei Heptares. Neurocrine outlined a deal that provides Sosei Heptares $100 million upfront, R&D expenses and a motherlode of milestones worth

Thrivent Financial for Lutherans raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,099 shares of the companys stock after buying an additional 124 shares during the quarter. Thrivent Financial for Lutherans []

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given a consensus rating of Hold by the twenty brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and nine have given a buy recommendation to the company. The average []

BMO Capital Markets began coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Thursday, Price Targets.com reports. The brokerage issued an underperform rating and a $76.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Citigroup lowered their target price on Neurocrine Biosciences from $132.00 []

Louisiana State Employees Retirement System reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,100 shares of the companys stock after selling 400 shares during the period. Louisiana State Employees Retirement Systems []

JPMorgan Chase & Co. upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a neutral rating to an overweight rating in a report released on Wednesday morning, Price Targets.com reports. They currently have $124.00 price objective on the stock. A number of other research firms also recently issued reports on NBIX. Royal Bank of Canada lowered their []

Comerica Bank raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 144,730 shares of the companys stock after purchasing an additional 29,856 shares during the quarter. Comerica Bank owned 0.15% of Neurocrine Biosciences worth $12,959,000 []

Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by expe

Investors have grown weary of unpredictable profitability and unexpected expenses.

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?